In 2018, 550,000 people were diagnosed with bladder cancer (BC), of which nearly 200,000
people died. Moreover, men are 4 times more likely than women to be diagnosed with BC …

Background: Immune profiles have been associated with bladder cancer outcomes and may
have clinical applications for prognosis. However, associations of detailed immune cell …

Background Non-muscle-invasive bladder cancer (NMIBC) patients receive frequent
monitoring because≥ 70% will have recurrent disease. However, screening is invasive …

Purpose We assessed the prognostic value of systemic immune-inflammation index (SII) to
refine risk stratification of the heterogeneous spectrum of patients with non-muscle-invasive …

Simple Summary The aim of this study was to evaluate the predictive and prognostic value
of the systemic immune-inflammation index (SII), which is based on peripheral blood …

Background The prognostic value of the systemic immune-inflammation index during
induction (ISII) remains unclear in non-muscle-invasive bladder cancer (NMIBC) patients …

Bladder cancer (BC) is one of the most prevalent malignancies in men. Understanding
molecular characteristics via studying signaling pathways has made tremendous …

Introduction Transurethral resection of bladder tumor with subsequent BCG immunotherapy
is the current gold standard in the treatment of high risk and some medium-risk non-muscle …

Background The systemic immune-inflammation index (SII) has emerged as a promising
marker predicting the prognosis of some cancers, while its role in urothelial carcinoma (UC) …

Introduction: In this study, we aimed to explore using the predictive role of systemic immune
inflammation index (SII) for responses of intravesical Bacillus Calmette-Guérin (BCG) …